Drug Information

Drug (ID: DG01027) and It's Reported Resistant Information

• Name: Glucosamine
• Synonyms: 2-Amino-2-Deoxy-D-Glucopyranose; 2-Amino-2-Deoxy-D-Glucopyranoside; 2-Amino-2-Deoxy-D-Glucose; 2-Amino-2-Deoxy-Glucopyranose; 2-Amino-2-Deoxy-Glucopyranoside; 2-Amino-2-Deoxy-Glucose; 2-Deoxy-2-Amino-D-Glucopyranose; 2-Deoxy-2-Amino-D-Glucopyranoside; 2-Deoxy-2-Amino-D-Glucose; 2-Deoxy-2-Amino-Glucopyranose; 2-Deoxy-2-Amino-Glucopyranoside; 2-Deoxy-2-Amino-Glucose; D-GlcN; D-Glucosamine; GlcN; Glucosamine; chitosamine; Glucosamine free base; D-(+)-Glucosamine; 2-amino-2-deoxyglucose; CHEBI:47977; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; 3416-24-8 (free base); 2-Aminoglucose; D-Glucose, 2-amino-2-deoxy-; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)tetrahydro-2H-pyran-2,4,5-triol; Glucosaminum [INN-Latin]; Glucosamina [INN-Spanish]; Mediflex; GlcNH2; 2-Deoxy-2-aminoglucose; Glucosamine (USAN/INN); Glucosamine [USAN:INN]; bmse000247; Epitope ID:151531; SCHEMBL167831; 2-Amino-2-deoxyhexopyranose #; CHEMBL493287; BBL009288; STK801823; AKOS005622471; (+)-2-amino-2-deoxy-D-glucopyranose; DB01296; DB-017621; C00329; D04334; Q327506; J-019472; WURCS=2.0/1,1,0/[a2122h-1x_1-5_2*N]/1/
• Indication:
  In total 1 Indication(s)
  Osteoarthritis [ICD-11: FA00-FA05]; Approved; [1]
• Target: Interleukin-1 beta (IL1B); IL1B_HUMAN; [1]
• Formula: C6H13NO5
• IsoSMILES: C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)N)O)O)O
• InChI: 1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6 /m1/s1
• InChIKey: MSWZFWKMSRAUBD-IVMDWMLBSA-N
• PubChem CID: 439213
• ChEBI ID: CHEBI:47977
• TTD Drug ID: D07NSU
• DrugBank ID: DB01296

Type(s) of Resistant Mechanism of This Drug

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Breast cancer [ICD-11: 2C60]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Breast cancer [ICD-11: 2C60.3]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HCC827 cells; Lung; Homo sapiens (Human); CVCL_2063
• In Vitro Model: MDA PCa 2b cells; Prostate; Homo sapiens (Human); CVCL_4748
• Experiment for Molecule Alteration: Quantitative RT-PCR assay
• Experiment for Drug Resistance: MTT assay; Flow cytometry
• Mechanism Description: This study was aimed at investigating the cytotoxicity and multi-drug resistance (MDR) reversal effect of Glucosamine (GlcN) on resistant BCRP-overexpressing breast cancer MCF-7/MX cells. These results proposed that glucosamine as a natural sugar could down regulate the BCRP expression and increased MX cytotoxicity in breast cancer cells. These results proposed that glucosamine as a natural sugar could down regulate the BCRP expression and increased MX cytotoxicity in breast cancer cells.

References

• Ref 1: Glucosamine attenuates drug resistance in Mitoxantrone-resistance breast cancer cells .J Pharm Pharmacol. 2021 Jun 8;73(7):922-927. doi: 10.1093/jpp/rgaa032. 10.1093/jpp/rgaa032